These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 21722900)

  • 1. Cardiovascular implications of HIV-induced dyslipidemia.
    Giannarelli C; Klein RS; Badimon JJ
    Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for management and treatment of dyslipidemia in HIV/AIDS.
    Sax PE
    AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
    Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
    Scordo KA
    Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
    Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
    BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
    Haser GC; Sumpio B
    J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia: management using optimal lipid-lowering therapy.
    Ito MK
    Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.
    Floris-Moore M; Howard AA; Lo Y; Schoenbaum EE; Arnsten JH; Klein RS
    AIDS Patient Care STDS; 2007 Jul; 21(7):479-91. PubMed ID: 17651029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.